Daptomycin vs Nisin
Cyclic lipodepsipeptide antibiotic containing 13 amino acids and a decanoyl lipid tail from Streptomyces roseosporus — FDA-approved as Cubicin for complicated skin infections (2003) and S. aureus bacteremia including right-sided endocarditis (2006), operating through calcium-dependent phosphatidylglycerol-specific membrane depolarization with rapid bactericidal activity against MRSA, VRE, and other multidrug-resistant Gram-positive pathogens
FDA GRAS-approved lantibiotic (34 amino acids) produced by Lactococcus lactis with a dual antimicrobial mechanism — binds lipid II to block cell wall synthesis AND forms 2 nm transmembrane pores for rapid bacterial killing at MIC 0.5-4 μg/mL against gram-positive pathogens including MRSA and Listeria monocytogenes — the only antimicrobial peptide with over 50 years of documented safe human consumption
Quick comparison
Dose range
Daptomycin
6–6 mg/kg
Nisin
10–50 mcg/mL
Frequency
Daptomycin
Once daily
Nisin
Once daily
Administration
Daptomycin
Intravenous infusion over 30 minutes (on the FDA label; 60 minutes for younger children)
Nisin
Oral (food-grade preservative, GRAS)
Cycle length
Daptomycin
7-14 days for skin infection, 2-6 weeks for bacteraemia
Nisin
Ongoing/indefinite
Onset speed
Daptomycin
Rapid (hours to days)
Nisin
Rapid (hours to days)
Evidence level
Daptomycin
Strong human trials (Phase 3 or FDA approved)
Nisin
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Fighting Drug-Resistant Infections
Bloodstream Infections
Skin Infection Treatment
Immune
Healing & Recovery
Anti-Aging
Compound specifications
Daptomycin
Molecular formula
C₇₂H₁₀₁N₁₇O₂₆
Molecular weight
1,620.69 Da
Half-life
Terminal half-life: 8-9 hours in healthy adults with normal renal function; supports once-daily dosing; post-antibiotic effect: 1-6 hours against S. aureus; renal dose adjustment: CrCl <30 mL/min — extend interval to every 48 hours
Bioavailability
IV: 100% (direct administration); not orally bioavailable (degraded in GI tract); inactivated in lungs by pulmonary surfactant
CAS number
103060-53-3
Nisin
Molecular formula
C143H230N42O37S7
Molecular weight
3,354.12 Da
Half-life
Rapidly degraded in GI tract by digestive proteases; stable for hours to days in food matrices at acidic pH; lanthionine ring structures resist most environmental proteases; thermostable (survives pasteurization)
Bioavailability
Degraded by pancreatic proteases in GI tract (does not affect gut microbiome at dietary levels); topical application achieves effective local concentrations; optimal activity at pH 2-6; lanthionine bridges provide significant protease resistance compared to linear peptides
CAS number
1414-45-5
Dosing compared
Daptomycin
Intravenous
4 mg/kg
Once every 24 hours · 7–14 days
The FDA-approved adult dose for complicated skin and skin-structure infections: 4 mg/kg every 24 hours for 7 to 14 days, intravenously in 0.9% sodium chloride, either as a 2-minute injection or a 30-minute infusion [6]. Below a creatinine clearance of 30 mL/min — including haemodialysis and CAPD — the same dose moves to every 48 hours, given after dialysis on dialysis days [6].
6 mg/kg
Once every 24 hours · 2–6 weeks
The FDA-approved adult dose for Staphylococcus aureus bloodstream infection, including right-sided infective endocarditis: 6 mg/kg every 24 hours for 2 to 6 weeks, every 48 hours below a creatinine clearance of 30 mL/min [6]. It is NOT approved for left-sided infective endocarditis, and NOT for pneumonia — pulmonary surfactant inactivates the drug directly [1][6].
8–12 mg/kg
Once every 24 hours · 2–6 weeks
Off-label in adults, and on-label in small children — the same numbers mean different things depending on who is being dosed. For children the label sets 12 mg/kg every 24 hours for ages 1 to 6 with S. aureus bacteraemia, 9 mg/kg for 7 to 11 and 7 mg/kg for 12 to 17, because clearance is faster [6]. In adults, above 6 mg/kg is off-label. The meta-analysis is not equivocal about the trade-off: in complicated bacteraemia and infective endocarditis, standard dosing succeeded significantly LESS often than high dosing (odds ratio 0.48, 95% CI 0.30-0.76 and 0.50, 0.30-0.82), and less often still against 8 mg/kg or more (0.38, 0.21-0.69 and 0.30, 0.15-0.60) — while the incidence of raised CPK was significantly lower on standard dosing [5]. In osteomyelitis and prosthetic infection, standard dosing did not do worse [5]. The label requires weekly CPK monitoring, more often in renal impairment or alongside a statin [6].
Nisin
Topical
10-50 mcg/mL applied to the affected area
Once or twice daily · Research protocol-dependent (typically 1-4 weeks)
Topical antimicrobial concentration range used in wound-care and infection-control research [5]. Investigational; not an approved human therapeutic route.
Best suited for
Daptomycin
Treatment of MRSA bacteremia and right-sided infective endocarditis (FDA-approved indication at 6 mg/kg)
Daptomycin is particularly well-suited for individuals focused on treatment of mrsa bacteremia and right-sided infective endocarditis (fda-approved indication at 6 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complicated skin and skin structure infections including surgical site infections and diabetic foot infections (FDA-approved at 4 mg/kg)
Daptomycin is particularly well-suited for individuals focused on complicated skin and skin structure infections including surgical site infections and diabetic foot infections (fda-approved at 4 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
VRE bloodstream infections and endocarditis when ampicillin-based therapy is not feasible
Daptomycin is particularly well-suited for individuals focused on vre bloodstream infections and endocarditis when ampicillin-based therapy is not feasible. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Outpatient parenteral antibiotic therapy (OPAT) for Gram-positive infections requiring IV treatment
Daptomycin is particularly well-suited for individuals focused on outpatient parenteral antibiotic therapy (opat) for gram-positive infections requiring iv treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Nisin
Food preservation as a natural antimicrobial alternative to chemical preservatives
Nisin is particularly well-suited for individuals focused on food preservation as a natural antimicrobial alternative to chemical preservatives. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Research into novel antimicrobial therapeutics based on lantibiotic scaffolds
Nisin is particularly well-suited for individuals focused on research into novel antimicrobial therapeutics based on lantibiotic scaffolds. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-Listeria and anti-Clostridium strategies in food safety and clinical settings
Nisin is particularly well-suited for individuals focused on anti-listeria and anti-clostridium strategies in food safety and clinical settings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of antimicrobial wound dressings and dental applications
Nisin is particularly well-suited for individuals focused on development of antimicrobial wound dressings and dental applications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Daptomycin
Common
- CPK elevation
- GI effects (nausea, diarrhea, vomiting)
- Headache and insomnia
- Injection site reactions
Uncommon
- Eosinophilic pneumonia
Serious
- Rhabdomyolysis
Nisin
Common
- No significant effects at dietary levels
- Mild GI discomfort at research doses
- Local irritation (topical use)
Uncommon
- Milk protein allergic reaction
- Gram-negative overgrowth
Serious
- No documented serious adverse effects
Safety & evidence
Daptomycin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for complicated skin and skin-structure infections (adults and children 1-17) and for Staphylococcus aureus bloodstream infection (adults including right-sided endocarditis, and children 1-17). NOT indicated for pneumonia, NOT for left-sided endocarditis, NOT recommended under 1 year of age.
Safety overview
The label's limitations of use are the sharpest safety facts here, because they describe failure rather than toxicity: daptomycin is not indicated for pneumonia, because pulmonary surfactant inactivates it directly [1][6], and not for left-sided infective endocarditis due to S. aureus [6]. On toxicity, myopathy is defined on the label as muscle aching or weakness with CPK above ten times the upper limit of normal, and rhabdomyolysis with or without acute renal failure has been reported; CPK is to be monitored weekly, and more often in renal impairment or alongside a statin [6]. The largest statin comparison found myalgias in 3 of 49 (6.1%) on the combination against 5 of 171 (2.9%) on daptomycin alone (p=0.38), and CPK above 1,000 U/L in 5 of 49 (10.2%) against 9 of 171 (5.3%) (p=0.32) — numerically worse, not statistically so, and reversible on stopping [2]. The label also warns of anaphylaxis, eosinophilic pneumonia, DRESS, tubulointerstitial nephritis, peripheral neuropathy, Clostridioides difficile diarrhoea, and reduced efficacy in adults with moderate baseline renal impairment [6]. Higher doses cost more muscle enzyme elevation: CPK rises were significantly more frequent above 6 mg/kg than at standard dose [5].
Contraindications
- Known hypersensitivity to daptomycin — the FDA label's only stated contraindication
- Pneumonia or any lower respiratory tract infection — pulmonary surfactant inactivates daptomycin directly, the first described case of organ-specific inhibition of an antibiotic, and the label states it is not indicated for pneumonia
- Left-sided infective endocarditis due to S. aureus — a stated limitation of use on the label
- Children under 1 year — the label does not recommend it, because of muscular, neuromuscular and nervous system effects seen in neonatal dogs
- Concurrent statins are not an absolute contraindication but need more frequent CPK monitoring; the largest comparison found numerically but not statistically higher musculoskeletal toxicity
Nisin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Nisin holds FDA GRAS status since 1988 with over 50 years of documented safe human consumption, making it the only antimicrobial peptide with this comprehensive long-term safety record. Oral LD50 of 174 mg/kg in mice (comparable to table salt) demonstrates extraordinary safety margin. Acceptable daily intake established at 0.13 mg/kg body weight with no reported serious adverse events at this or higher levels. Primary risk is milk protein contamination during production, requiring screening for lactose-intolerant or milk-allergic individuals.
Contraindications
- Known hypersensitivity to nisin or Lactococcus lactis-derived products
- Milk protein allergy — nisin production involves dairy-associated bacteria and preparations may contain trace milk proteins
- Pregnancy and breastfeeding at therapeutic (non-dietary) doses — standard dietary exposure through preserved foods is considered safe
- Active inflammatory bowel disease — potential for local irritation at high oral concentrations exceeding normal dietary levels
Which is right for you?
Choose Daptomycin if...
- Treatment of MRSA bacteremia and right-sided infective endocarditis (FDA-approved indication at 6 mg/kg)
- Complicated skin and skin structure infections including surgical site infections and diabetic foot infections (FDA-approved at 4 mg/kg)
- VRE bloodstream infections and endocarditis when ampicillin-based therapy is not feasible
- Outpatient parenteral antibiotic therapy (OPAT) for Gram-positive infections requiring IV treatment
Choose Nisin if...
- Food preservation as a natural antimicrobial alternative to chemical preservatives
- Research into novel antimicrobial therapeutics based on lantibiotic scaffolds
- Anti-Listeria and anti-Clostridium strategies in food safety and clinical settings
- Development of antimicrobial wound dressings and dental applications